CompletedNot Applicable

Metastatic Colorectal Cancer. Real-World Data Analysis.

Turkey (Türkiye)1,750 participantsStarted 2020-08-01

Plain-language summary

The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who have been histologically diagnosed with mCRC
✓. Patients over the age of 18
✓. Patients receiving at least a cycle systemic treatment for metastatic disease
✓. RAS wild type patients
✓. Patients who has demographic, histopathological and clinical information

Exclusion criteria

✕. Patients diagnosed as mCRC but only referred to BSC
✕. Patients with RAS mutation
✕. Patients who were included in any clinical trial except standard treatments during their treatment

What they're measuring

Percentage of use anti-EGFR agents

Timeframe: throughout of treatment, 3 years

Progression Free Survival (PFS)

Timeframe: 3 years treatment

Trial details

NCT IDNCT04757311

SponsorIstanbul Medeniyet University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-04-30

View on ClinicalTrials.gov More Metastatic Colorectal Cancer trials